Junia V. Melo

15.2k citations

119 papers · 10.2k indexed · 4 hit papers · h-index 49

Impact in

Hematology top 0.05%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 94
- Chronic Myeloid Leukemia Treatments 89
- Acute Myeloid Leukemia Research 13
Genetics 84
- Chronic Lymphocytic Leukemia Research 77
- Myeloproliferative Neoplasms: Diagnosis and Treatment 8

Co-authors: John M. Goldman Michael W. Deininger David Barnes Beate Schultheis Daniel Catovsky David A. G. Galton Jane F. Apperley Nicholas Lydon
Journals: Blood (37 papers)British Journal of Haematology (13 papers)Hematology (5 papers)Clinical Cancer Research (4 papers)Seminars in Hematology (4 papers)
Partner nations: United Kingdom Australia United States

In The Last Decade

Junia V. Melo

117 papers receiving 9.9k citations

Hit Papers

align trajectories log scale

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study 2013 · 508 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Blood
2003 New England Journal of Medicine
2000 Blood
2000 Blood

Peers

Countries citing papers authored by Junia V. Melo

Since Specialization

Citations

This map shows the geographic impact of Junia V. Melo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junia V. Melo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junia V. Melo more than expected).

Fields of papers citing papers by Junia V. Melo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junia V. Melo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junia V. Melo. The network helps show where Junia V. Melo may publish in the future.

Co-authors

The 25 scholars most cited alongside Junia V. Melo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Junia V. Melo Line = papers co-authored together Junia V. Melo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	How to perform a high-quality peer review PubMed ·Mohamad Mohty, Junia V. Melo	2025	0
2	Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients Cancer Letters ·Ruriko Tanaka, Shinya Kimura, Eishi Ashihara, Mariko Yoshimura, Naoto Takahashi, Hisashi Wakita, Kuniaki Itoh, Kaichi Nishiwaki, Kenshi Suzuki, Rina Nagao, Hisayuki Yao, Yoshihiro Hayashi, Sakiko Satake, Hideyo Hirai, Ken-ichi Sawada, Oliver G. Ottmann, Junia V. Melo, Taira Maekawa	2011	15
3	Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells British Journal of Pharmacology ·Jost Klawitter, Douglas J. Kominsky, Jaimi L. Brown, Uwe Christians, Dieter Leibfritz, Junia V. Melo, Sabine Eckhardt, Natalie J. Serkova	2009	55
4	Proteasome proteolytic profile is linked to Bcr-Abl expression Experimental Hematology ·Lisa Crawford, Phlip Windrum, Laura Magill, Junia V. Melo, Lynn McCallum, Mary Frances McMullin, Huib Ovaa, Brian Walker, Alexandra E. Irvine	2009	16
5	Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis Clinical Cancer Research ·Gordon Strathdee, Tessa L. Holyoake, Alyson Sim, Anton Parker, David Oscier, Junia V. Melo, Stefan Meyer, Tim Eden, Anne M. Dickinson, Joanne C. Mountford, Heather G. Jørgensen, Richard Soutar, Robert Brown	2007	103
6	Production of P‐glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first‐line chemotherapy in advanced breast cancer International Journal of Cancer ·Selina Raguz, Rebecca A. Randle, Eva Sharpe, John A. Foekens, Anieta M. Sieuwerts, Marion E. Meijer‐van Gelder, Junia V. Melo, Christopher F. Higgins, Ernesto Yagüe	2007	16
7	Chronic myeloid leukaemia as a model of disease evolution in human cancer Nature reviews. Cancer ·Junia V. Melo, David Barnes	2007	434
8	Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib Clinical Cancer Research ·Paul La Rosée, Taiping Jia, Shadmer Demehri, Nicolai Härtel, Peter de Vries, Lynn Bonham, David Hollenback, Jack W. Singer, Junia V. Melo, Brian Druker, Michael W. Deininger	2006	23
9	Primitive, Quiescent and Difficult to Kill: The Role of Non-Proliferating Stem Cells in Chronic Myeloid Leukemia Cell Cycle ·David Barnes, Junia V. Melo	2006	97
10	Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease International Journal of Hematology ·Chikashi Yoshida, Junia V. Melo	2004	37
11	Switching off oncogenic signals in chronic myeloid leukaemia The Hematology Journal ·Junia V. Melo, David Barnes	2004	5
12	Management of chronic myeloid leukemia: Targets for molecular therapy Seminars in Hematology ·David J Barnes, Junia V. Melo	2003	4
13	Cytogenetic and Molecular Genetic Aspects of Chronic Myeloid Leukaemia Acta Haematologica ·David Barnes, Junia V. Melo	2002	67
14	Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism Blood ·Beate Schultheis, Melina Carapeti-Marootian, Andreas Hochhaus, Andreas Weiβer, John M. Goldman, Junia V. Melo	2002	70
15	Elimination of the Truncated Message from the Herpes Simplex Virus Thymidine Kinase Suicide Gene Molecular Therapy ·David Chalmers, Christophe Ferrand, Jane F. Apperley, Junia V. Melo, Saskia B. Ebeling, I Newton, Anne Duperrier, Anton Hagenbeek, Elaine Garrett, Pierre Tiberghien, Marina Garín	2001	42
16	BCL10 deletions in haematological malignancies: a cloning artefact? British Journal of Haematology ·Veronique Duke, Aarti Kapoor, Clair Gricks, Junia V. Melo, Letizia Foroni	2000	4
17	Characterization of Recombination Events Leading to the Production of an Ecotropic Replication-Competent Retrovirus in a GP+envAM12-Derived Producer Cell Line Virology ·Elaine Garrett, Angela Miller, John M. Goldman, Jane F. Apperley, Junia V. Melo	2000	18
18	Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma Cancer Gene Therapy ·Carmen Rivas, P Chandler, Junia V. Melo, Elizabeth Simpson, Jane F. Apperley	2000	5
19	2 BCR-ABL gene variants Baillière s Clinical Haematology ·Junia V. Melo	1997	99
20	BCR‐ABL‐positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions British Journal of Haematology ·Andrew Spencer, Xiu‐Hua Yan, Andrew Chase, J M Goldman, Junia V. Melo	1996	6

About Junia V. Melo

Junia V. Melo is a scholar working on Hematology, Genetics, Rheumatology, Pathology and Forensic Medicine and Immunology, having authored 119 papers that have together received 10.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (89 papers), Chronic Lymphocytic Leukemia Research (77 papers), Eosinophilic Disorders and Syndromes (46 papers), Lymphoma Diagnosis and Treatment (18 papers), Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and HER2/EGFR in Cancer Research (6 papers). The work is most often cited by research in Hematology (7.3k citations), Genetics (5.6k citations), Rheumatology (3.2k citations), Oncology (1.8k citations) and Pathology and Forensic Medicine (1.1k citations). Junia V. Melo has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include John M. Goldman, Michael W. Deininger, David Barnes, Beate Schultheis, Daniel Catovsky, David A. G. Galton, Jane F. Apperley, Nicholas Lydon, Timothy P. Hughes and François Xavier Mahon. Their work appears in journals such as Blood, British Journal of Haematology, Hematology, Clinical Cancer Research and Seminars in Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact